Get the Stockscreener App
6.48
6.75%
0.41
Cns Pharmaceuticals Inc stock is traded at $6.48, with a volume of 78,958.
It is up +6.75% in the last 24 hours and down -26.53% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$6.07
Open:
$6.46
24h Volume:
78,958
Relative Volume:
3.09
Market Cap:
$3.28M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0916
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
+27.31%
1M Performance:
-26.53%
6M Performance:
-83.28%
1Y Performance:
-93.76%
1-Day Range:
$5.76
$6.65
1-Week Range:
$5.1101
$7.32
52-Week Range:
$4.93
$221.94
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
6.48 | 3.28M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals Surges 30% Intraday: What's Fueling This Biotech Breakout? - AInvest
Will CNS Pharmaceuticals Inc. Sustain Its Chart Breakout2025 Earnings Surprises & AI Powered Buy/Sell Recommendations - metal.it
Is it too late to sell CNS Pharmaceuticals Inc.July 2025 Levels & Precise Buy Zone Identification - Newser
What is the earnings history of CNS Pharmaceuticals Inc.Portfolio Gains Report & Safe Entry Point Identification - thegnnews.com
Predicting CNS Pharmaceuticals Inc. trend using moving averagesWeekly Gains Report & Stepwise Entry/Exit Trade Alerts - Newser
Heatmap analysis for CNS Pharmaceuticals Inc. and competitorsJuly 2025 Short Interest & AI Powered Market Entry Strategies - Newser
Detecting price anomalies in CNS Pharmaceuticals Inc. with AI2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
CNS Pharmaceuticals Inc. stock prediction for this weekWeekly Investment Report & Fast Entry Momentum Alerts - Newser
Will CNS Pharmaceuticals Inc. outperform the marketJuly 2025 Macro Moves & Low Risk Entry Point Guides - Newser
CNS Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
What’s the recovery path for long term holders of CNS Pharmaceuticals Inc.2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
Market reaction to CNS Pharmaceuticals Inc.’s recent newsRisk Management & Fast Moving Market Watchlists - Newser
Why CNS Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Stock Summary & Verified Entry Point Signals - Newser
Using data tools to time your CNS Pharmaceuticals Inc. exitMarket Weekly Review & Fast Entry High Yield Stock Tips - Newser
What recovery options are there for CNS Pharmaceuticals Inc.2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - Newser
CNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last year - TipRanks
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series, Biotech, MedTech - MarketScreener
Brain Cancer Breakthrough: CNS Pharma's TPI 287 Shows 52% Response Rate in Phase 1 GBM Trial - Stock Titan
CNS Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Brain Cancer Treatment Developer CNS Pharmaceuticals Joins Webull's Virtual Biotech Conference - Stock Titan
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - FinancialContent
Earnings visualization tools for CNS Pharmaceuticals Inc.AI Generated Momentum Stock Forecast Guide - Newser
CNS Pharmaceuticals CNSP 2025Q2 Earnings Preview Downside Risk Amid Market Uncertainties - AInvest
What makes CNS Pharmaceuticals Inc. stock price move sharplyTechnical Entry Plan with Risk Minimization - Newser
Can machine learning forecast CNS Pharmaceuticals Inc. recoveryMarket Stability and Long-Term Growth Outlook - Newser
Central Nervous System (CNS) Therapeutics Market Forecast - openPR.com
What analysts say about CNS Pharmaceuticals Inc. stockGet alerts on high-potential market moves - Jammu Links News
Is CNS Pharmaceuticals Inc. stock overvalued or undervaluedRapid growth trajectories - Jammu Links News
Should I hold or sell CNS Pharmaceuticals Inc. stock in 2025Free Trend-Following Techniques - Jammu Links News
When is CNS Pharmaceuticals Inc. stock expected to show significant growthRapid-fire capital growth - Jammu Links News
CNS Pharmaceuticals Inc. Stock Analysis and ForecastPhenomenal capital gains - Jammu Links News
What catalysts could drive CNS Pharmaceuticals Inc. stock higher in 2025Maximize returns with strategic portfolio planning - Jammu Links News
Why is CNS Pharmaceuticals Inc. stock attracting strong analyst attentionDynamic profit expansion - Jammu Links News
What are analysts’ price targets for CNS Pharmaceuticals Inc. in the next 12 monthsAmplify your gains with low-risk picks - Jammu Links News
What is the risk reward ratio of investing in CNS Pharmaceuticals Inc. stockHigh-performance stocks for savvy investors - Jammu Links News
How volatile is CNS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms consistently - Jammu Links News
What is the dividend policy of CNS Pharmaceuticals Inc. stockFinancial News Outlook For 2025 - Jammu Links News
Ranking CNS Pharmaceuticals Inc. among high performing stocks via toolsHigh Probability Trade Plan with Indicators - Newser
CNS Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySwing Setup With Technical Confirmation Explained - metal.it
How does CNS Pharmaceuticals Inc. compare to its industry peersBeginner Investor Watchlist For 2025 - Jammu Links News
Published on: 2025-07-28 14:09:47 - metal.it
Will CNS Pharmaceuticals Inc. outperform the market Free Buy Low Sell High Stock Watch - Newser
Is it the right time to buy CNS Pharmaceuticals Inc. stockHigh-yield investments - Jammu Links News
What makes CNS Pharmaceuticals Inc. stock price move sharply 2-Day Signal Watch with Forecast Outcome - metal.it
How strong is CNS Pharmaceuticals Inc. company’s balance sheetExplosive earnings growth - Jammu Links News
Does CNS Pharmaceuticals Inc. stock perform well during market downturnsUnprecedented market success - Jammu Links News
Published on: 2025-07-27 20:34:14 - Jammu Links News
What drives CNS Pharmaceuticals Inc. stock priceFree Stock Movement Tracking - Autocar Professional
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):